Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).
Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.
An Adult Case of Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Multiphasic Acute Disseminated Encephalomyelitis at 33-year Intervals.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity.
The olfactory vector hypothesis of neurodegenerative disease: is it viable?
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Aquatic exercise effect on fatigue and quality of life of women with multiple sclerosis: a randomized controlled clinical trial.
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy.
Plasma exchange in severe attacks of neuromyelitis optica.

Pages